Novavax Inc
NVAX6.745USD
+0.185+2.82%
Market hours （ET）Quotes delayed by 15 min
1.09BMarket Cap
2.28P/E TTM
More Details of Novavax Inc Company
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Company Info
Ticker SymbolNVAX
Company nameNovavax Inc
IPO dateMay 16, 1973
CEOMr. John C. Jacobs
Number of employees952
Security typeOrdinary Share
Fiscal year-endMay 16
Address700 Quince Orchard Road
CityGAITHERSBURG
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20878
Phone12402682000
Websitehttps://www.novavax.com/?locale=US
Ticker SymbolNVAX
IPO dateMay 16, 1973
CEOMr. John C. Jacobs
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
35.11K
+42.20%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
31.97K
--
Mr. James Patrick (Jim) Kelly
Mr. James Patrick (Jim) Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Dr. Robert Walker, M.D.
Dr. Robert Walker, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
No Data
By RegionUSD
Name
Revenue
Proportion
Canada
575.67M
86.38%
Rest of the world
43.29M
6.50%
United States
39.41M
5.91%
Europe
8.09M
1.21%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jun 4
Updated: Wed, Jun 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.62%
Investment Advisor/Hedge Fund
18.46%
Hedge Fund
10.75%
Corporation
8.26%
Research Firm
4.80%
Pension Fund
0.81%
Individual Investor
0.52%
Bank and Trust
0.43%
Venture Capital
0.04%
Other
33.30%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
550
108.02M
66.69%
-12.99M
2025Q1
575
113.82M
70.29%
-16.33M
2024Q4
593
111.51M
69.72%
-5.93M
2024Q3
597
103.31M
64.96%
-4.25M
2024Q2
652
92.80M
65.79%
-10.97M
2024Q1
753
86.51M
64.06%
-11.91M
2023Q4
848
86.68M
74.23%
+6.21M
2023Q3
919
70.31M
60.51%
-6.00M
2023Q2
957
58.87M
62.55%
-19.22M
2023Q1
1015
61.08M
70.93%
-3.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
15.64M
9.66%
-57.51K
-0.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.56M
7.14%
-518.90K
-4.30%
Mar 31, 2025
Shah Capital Management, Inc.
11.13M
6.87%
-17.00K
-0.15%
Mar 31, 2025
State Street Global Advisors (US)
7.04M
4.35%
-662.21K
-8.60%
Mar 31, 2025
Sanofi SA
6.88M
4.25%
--
--
Mar 31, 2025
SK Bioscience Co., Ltd.
6.50M
4.01%
--
--
May 10, 2024
Coatue Management, L.L.C.
3.84M
2.37%
+3.84M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
3.76M
2.32%
+106.31K
+2.91%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.26M
2.01%
-2.53M
-43.68%
Mar 31, 2025
Park West Asset Management LLC
2.53M
1.56%
+2.53M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Nanotechnology ETF
2.42%
iShares Genomics Immunology and Healthcare ETF
2.14%
Virtus LifeSci Biotech Products ETF
1.7%
ALPS Medical Breakthroughs ETF
0.69%
SPDR S&P Biotech ETF
0.41%
Direxion Daily S&P Biotech Bull 3X Shares
0.23%
Invesco Nasdaq Biotechnology ETF
0.11%
First Trust Small Cap Growth AlphaDEX Fund
0.11%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
View more
ProShares Nanotechnology ETF
Proportion2.42%
iShares Genomics Immunology and Healthcare ETF
Proportion2.14%
Virtus LifeSci Biotech Products ETF
Proportion1.7%
ALPS Medical Breakthroughs ETF
Proportion0.69%
SPDR S&P Biotech ETF
Proportion0.41%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.23%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
iShares Biotechnology ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
